[Treatment of uveitis-associated refractory ocular hypotony with topical ibopamine]

BACKGROUND: Ibopamine is a non-selective dopamine- and adrenalin-receptor agonist that has been shown to cause pupillary dilation and an increase in aqueous humour secretion. This novel drug can be used as a mydriatic agent, as a provocative test in open-angle glaucoma, and for the treatment of persisting ocular hypotony. HISTORY AND SIGNS: This 47-year-old man had a history of uveitis associated with Crohn's disease. Six years after deep sclerectomy for uveitic secondary glaucoma, he developed severe hypotony in his left eye with drop of visual acuity (VA). The hypotony did not respond to topical steroid treatment. 2 % Ibopamine solution was ordered t. i. d. concomitant to 1 % prednisolone acetate. THERAPY AND OUTCOME: Intraocular pressure (IOP) began to rise after 3 weeks of Ibopamine treatment and returned to normal (12 mmHg) with continuous recovery of VA after 8 weeks. Ibopamine was discontinued at an IOP of 16 mmHg after a course of 12 weeks. IOP and VA remained stable during the 12-month follow-up period. CONCLUSIONS: Ibopamine 2 % eye drops in combination with topical steroids are a therapeutic option in uveitis-associated ocular hypotony.

Antiproliferative effects of mistletoe (Viscum album L.) extract in urinary bladder carcinoma cell lines

BACKGROUND: The aim of the study was to evaluate the antiproliferative potency of Viscum album extract (VA-E) in human bladder carcinoma cell lines with regard to its possible use for intravesical therapy of superficial bladder cancer. MATERIALS AND METHODS: Proliferation (MTT-test or 3H-thymidine incorporation), necrotic disintegration (3H-thymidine release of prelabelled cells) and portions of apoptotic and/or necrotic cells (Annexin-V binding, propidium iodide (PI) labelling and DNA-fluorescence profiles by flow cytometry) were measured in four different human bladder carcinoma cell lines (T24, TCCSUP, J82 and UM-UC3) cultured in vitro. RESULTS: Antiproliferative effects of VA-E were observed in the four bladder carcinoma cell lines tested. Metabolic activity could also be completely abrogated by short-time contact of the cells with VA-E. Apoptosis and necrosis, as underlying mechanisms of action, were differentially expressed by the different cell lines. CONCLUSION: VA-E and cytotoxic proteins, i.e., mistletoe lectins (ML) and viscotoxins (VT), were able to block the growth of bladder carcinoma cells. Together with the immunomodulating properties of VA-E, the observed antiproliferative potency might give a rationale for the topical intravesical application of VA-E for the treatment of superficial bladder cancer.

A comparison of techniques for forecasting utilization of Veterans Affairs hospitals

This study demonstrated that accurate, short-term forecasts of Veterans Affairs (VA) hospital utilization can be made using the Patient Treatment File (PTF), the inpatient discharge database of the VA. Accurate, short-term forecasts of two years or less can reduce required inventory levels, improve allocation of resources, and are essential for better financial management. These are all necessary achievements in an era of cost-containment.^ Six years of non-psychiatric discharge records were extracted from the PTF and used to calculate four indicators of VA hospital utilization: average length of stay, discharge rate, multi-stay rate (a measure of readmissions) and days of care provided. National and regional levels of these indicators were described and compared for fiscal year 1984 (FY84) to FY89 inclusive.^ Using the observed levels of utilization for the 48 months between FY84 and FY87, five techniques were used to forecast monthly levels of utilization for FY88 and FY89. Forecasts were compared to the observed levels of utilization for these years. Monthly forecasts were also produced for FY90 and FY91.^ Forecasts for days of care provided were not produced. Current inpatients with very long lengths of stay contribute a substantial amount of this indicator and it cannot be accurately calculated.^ During the six year period between FY84 and FY89, average length of stay declined substantially, nationally and regionally. The discharge rate was relatively stable, while the multi-stay rate increased slightly during this period. FY90 and FY91 forecasts show a continued decline in the average length of stay, while the discharge rate is forecast to decline slightly and the multi-stay rate is forecast to increase very slightly.^ Over a 24 month ahead period, all three indicators were forecast within a 10 percent average monthly error. The 12-month ahead forecast errors were slightly lower. Average length of stay was less easily forecast, while the multi-stay rate was the easiest indicator to forecast.^ No single technique performed significantly better as determined by the Mean Absolute Percent Error, a standard measure of error. However, Autoregressive Integrated Moving Average (ARIMA) models performed well overall and are recommended for short-term forecasting of VA hospital utilization. ^

Colored dissolved organic matter (cDOM) absorption measurements in terrestrial water objects of Yamal, Yavai and Gydan Peninsula

The datasets present measurements of cDOM absorption in lakes, rivers and streams of Yamal and Gydan Peninsula area during the summer periods from 2012-2014 and 2016. In summer seasons of 2012 - 2013 water samples was collected during "Yamal-Arctic" Expedition. All of the research areas were located near the coastline of Yamal, Yavay, and Gydan Peninsula and Bely Island. In 2012 water samples from rivers, lakes and streams were taken near New Port, Cape Kamenny and Tambey settlements and in basins (water catchments) of the Sabetta, Seyakha, Yuribey (Baydaratskaya Bay, Gydan Peninsula) and Mongocheyakha rivers. In 2013 water samples from rivers, lakes and streams were taken in the Yavai Peninsula, Yayne Vong bay and in the basins (water catchments) of the Sabetta, Mongocheyakha and Yuribey (Gydan Peninsula) rivers. In 2014 lakes were sampled in the Erkuta River basin, south of Yamal Peninsula. In 2016 lakes and rivers were sampled it the Erkuta River basin and Polar Ural area. cDOM is operationally defined by the chosen filter pore size. Samples have been consistently filtrated through 0.7 µm pore size glas fibre filters. cDOM filtrates have been stored in darkness and have been measured after the expedition using the dual-beam Specord200 laboratory spectrometer (Jena Analytik) at the Otto Schmidt Laboratory OSL, Arctic and Antarctic Research Institute, St. Petersburg, Russia. The OSL cDOM protocol (Heim and Roessler, 2016) prescribes 3 Absorbance (A) measurements per sample from UV to 750 nm against ultra-pure water. The absorption coefficient, a, is calculated by a = 2.303A/L, where L is the pathlength of the cuvette [m], and the factor 2.303 converts log10 to loge. The output of the calculation is a continuous spectrum of a. The cDOM a spectra are used to determine the exponential slope value for specific wavelength ranges, S by fitting the data between min and max wavelength to an exponential function. We provide cDOM absorption coefficients for the wavelengths 254, 260, 350, 375, 400, 412, 440, 443 nm [1/m] and Slope values for three different UV, VIS, wavelength ranges: 275 to 295 nm, 350 to 400 nm, 300 to 500 nm [1/m]. All data were carried out by scientists from Arctic and Antarctic Research Institute and Saint Petersburg State University of Russia during "Yamal-Arctic" expeditions in 2012-2013, RFBR project No 14-04-10065 in 2014, No 14-05-00787 in 2016.